title: Management of chronic hepatitis C in French departments of internal medicine and infectious diseases.
abstract: This prospective, multicentre study was conducted during 2-30 April 2001 in the internal medicine/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic evaluation of HCV infection performed (HCV RNA, genotype, liver biopsy); determine the proportion and characteristics of patients receiving antiviral treatment; and determine if any changes in these parameters had occurred between 1995 and 2001. Patients whom had a complete pre-therapeutic evaluation (39%, 709/1834) and received antiviral treatment (38%, 690/1830) were more likely to have abnormal liver biochemistry, cirrhosis and cryoglobulinaemia (P < 0.001). Injecting drug users and HIV-co-infected patients were less likely to have a complete pre-therapeutic evaluation or receive antiviral treatment (P < 0.001). A complete pre-therapeutic evaluation was more often performed in 2001 than in 1995 (39% vs. 6%, P < 0.001), including qualitative HCV RNA testing (91% vs. 68%, P < 0.001), genotyping (59% vs. 7%, P < 0.001) and a liver biopsy (60% vs. 29%, P < 0.001). The frequency of anti-HCV treatment approximately doubled between 1995 and 2001 (20% vs. 38%, P < 0001). Although adherence to consensus recommendations regarding pre-therapeutic evaluation is not ideal, a substantial improvement has occurred since 1995. Nevertheless, means of increasing the availability of antiviral therapies, particularly for patients with HIV co-infection or injecting drug use, require further study.
authors.affiliation: Department of Internal Medicine, Hôpital La Pitié-Salpêtrière, 83 Boulevard de l'Hôpital, 75651, Paris, France. patrice.cacoub@psl.ap-hop-paris.fr
authors.forename: P
authors.initials: P
authors.lastname: Cacoub
authors.forename: I
authors.initials: I
authors.lastname: Goderel
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: D
authors.initials: D
authors.lastname: Sene
authors.forename: R P
authors.initials: RP
authors.lastname: Myers
authors.forename: L
authors.initials: L
authors.lastname: Alric
authors.forename: V
authors.initials: V
authors.lastname: Loustaud-Ratti
authors.forename: P
authors.initials: P
authors.lastname: Melin
authors.forename: N
authors.initials: N
authors.lastname: Limal
authors.forename: D
authors.initials: D
authors.lastname: Ouzan
authors.forename: C
authors.initials: C
authors.lastname: Perronne
authors.forename: F
authors.initials: F
authors.lastname: Carrat
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D005260:Female; D005602:France; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007388:Internal Medicine / Q000706:statistics & numerical data; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis; D015819:Substance Abuse, Intravenous
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral